[1]
Barot, K.P.; Nikolova, S.; Ivanov, I.; Ghate, M.D. Novel anticancer agents and targets: Recent advances and future perspectives. Mini Rev. Med. Chem., 2013, 13, 1239-1255.
[2]
Kaplan-Ozen, C.; Tekiner-Gulbas, B.; Foto, E.; Yildiz, I.; Diril, N.; Aki, E.; Yalcin, I. Benzothiazole derivatives as human DNA topoisomerase II alpha inhibitors. Med. Chem. Res., 2013, 22, 5798-5808.
[3]
Prasad, V.V.S.R.; Reddy, G.D.; Kathmann, I.; Amareswararao, M. Peters, G.J. Nitric oxide releasing acridone carboxamide derivatives as reverters of doxorubicin resistance in MCF7/Dx cancer cells. Bioorg. Chem., 2016, 64, 51-58.
[4]
Geddes, C.D. Optical thin film polymeric sensors for the determination of aqueous chloride, bromide and iodide ions at high pH, based on the quenching of fluorescence of two acridinium dyes. Dyes Pigm., 2000, 45, 243-251.
[5]
Dana, S.; Prusty, D.; Dhayal, D.; Gupta, M.K.; Dar, A.; Sen, S.; Mukhopadhyay, P.; Adak, T.; Dhar, S.K. Potent antimalarial activity of acriflavine in vitro and in vivo. ACS Chem. Biol., 2014, 9, 2366-2373.
[6]
Di Giorgio, C.; De Meo, M.; Chiron, J.; Delmas, F.; Nikoyan, A.; Jean, S.; Dumenil, G.; Timon-David, P.; Galy, J.P. Synthesis and antileishmanial activities of 4,5-di-substituted acridines as compared to their 4-mono-substituted homologues. Bioorg. Med. Chem., 2005, 13, 5560-5568.
[7]
Gamega, S.A.; Spicer, J.A.; Atwell, G.J.; Finlay, G.J.; Baguley, B.C.; Denny, W.A. Structure-activity relationships for substituted bis(acridine-4-carboxamides): A new class of anticancer agents. J. Med. Chem., 1999, 42, 2383-2393.
[8]
Gensicka-Kowalewska, M.; Cholewiński, G.; Dzierzbicka, K. Recent developments in the synthesis and biological activity of acridine/acridone analogues. RSC Advances, 2017, 7, 15776-15804.
[9]
Malachowska-Ugarte, M.; Cholewinski, G.; Dzierzbicka, K.; Trzonkowski, P. Synthesis and biological activity of novel mycophenolic acid conjugates containing nitro-acridine/acridone derivatives. Eur. J. Med. Chem., 2012, 54, 197-201.
[10]
Kukowska, M. Amino acid or peptide conjugates of acridine/ acridone and quinoline/quinolone-containing drugs. A critical examination of their clinical effectiveness within a twenty-year timeframe in antitumor chemotherapy and treatment of infectious diseases. Eur. J. Pharm. Sci., 2017, 109, 587-615.
[11]
Kukowska-Kaszuba, M.; Dzierzbicka, K. Synthesis and structure-activity studies of peptide-acridine/acridone conjugates. Curr. Med. Chem., 2007, 14, 3079-3104.
[12]
Siebert, A.; Gensicka-Kowalewska, M.; Cholewiński, G.; Dzierzbicka, K. Tuftsin–properties and analogs. Curr. Med. Chem., 2017, 24, 3711-3727.
[13]
Cichorek, M.; Kozłowska, K.; Bryl, E. The activity of caspases in spontaneous and camptothecin-induced death of melanotic and amelanotic melanoma cells. Cancer Biol. Ther., 2007, 6, 346-353.
[14]
Kofoed, T.; Hansen, H.F.; Ørum, H.; Koch, T. PNA synthesis using a novel Boc/acyl protecting group strategy. J. Pept. Sci., 2001, 7, 402-412.
[15]
Dzierzbicka, K.; Trzonkowski, P.; Sewerynek, P.; Kolodziejczyk, A.M.; Myśliwski, A. Synthesis and biological activity of tuftsin, its analogue and conjugates containing muramyl dipeptides or nor-muramyl dipeptides. J. Pept. Sci., 2005, 11, 123-135.
[16]
Dzierzbicka, K.; Wardowska, A.; Rogalska, M.; Trzonkowski, P. New conjugates of muramyl dipeptide and nor-muramyl dipeptide linked to tuftsin and retro-tuftsin derivatives significantly influence their biological activity. Pharmacol. Rep., 2012, 64, 217-223.
[17]
Januchta, W.; Serocki, M.; Dzierzbicka, K.; Cholewinski, G.; Skladanowski, A. Synthesis of functionalized new conjugates of batracylin with tuftsin/retro-tuftsin derivatives and their biological evaluation. Eur. J. Med. Chem., 2015, 106, 85-94.
[18]
Ledochowski, A. Ledacrin - anticancerous medicine 1-nitro-9(3-dimethyloamino-propylamino)-acridine-2HCl-H2O. Mater. Med. Pol., 1976, 8, 237-251.
[19]
Capps, D.B. Substituted 1-amino-4-nitroacridinones, pharmaceutical
compositions comprising the same and processes for their production.
European Patent E.P. 0145226, October 31, 1984.
[20]
Dzierzbicka, K.; Kołodziejczyk, A.M.; Wysocka-Skrzela, B.; Myśliwski, A.; Sosnowska, D. Synthesis and antitumor activity of conjugates of muramyldipeptide, normuramyl dipeptide, and desmuramylpeptides with acridine/acridone derivatives. J. Med. Chem., 2001, 44, 3606-3615.
[21]
Bomirski, A.; Slominski, A.; Bigda, J. The natural history of a family of transplantable melanomas in hamsters. Cancer Metastasis Rev., 1988, 7, 95-118.
[22]
Bielarczyk, H.; Jankowska, A.; Madziar, B.; Matecki, A.; Michno, A.; Szutowicz, A. Differential toxicity of nitric oxide, aluminum, and amyloid b-peptide in SN56 cholinergic cells from mouse septum. Neurochem. Int., 2003, 42, 323-331.
[23]
Smolewski, P.; Grabarek, J.; Halicka, H.D.; Darzynkiewicz, Z. Assay of caspase activation in situ combined with probing plasma membrane integrity to detect three distinct stages of apoptosis. J. Immunol. Methods, 2002, 265, 111-121.
[24]
Darżynkiewicz, Z.; Williamson, B.; Carswell, E.; Old, L. Cell cycle-specific effects of tumor necrosis factor. Cancer Res., 1984, 44, 83-90.
[25]
Guo, H.F.; Kooi, C.W.V. Neuropilin functions as an essential cell surface receptor. J. Biol. Chem., 2015, 290, 29120-29126.
[26]
Graziani, G.; Lacal, P.M. Neuropilin-1 as therapeutic target for malignant melanoma. Front. Oncol., 2015, 5, 125-129.
